| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human Ang1-7 concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human Ang1-7. During the reaction, Human Ang1-7 in the sample or standard competes with a fixed amount of Human Ang1-7 on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human Ang1-7. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human Ang1-7 in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human Ang1-7 in samples.No significant cross-reactivity or interference between Human Ang1-7 and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant Ang1-7 standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts (2022) Cardiovascular Diabetology. 10.1186/s12933-022-01573-x
Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1–7) as a sensitizer for chemotherapy and immunotherapy in breast cancer (2022) BIOLOGICAL PROCEDURES ONLINE. 10.1186/s12575-022-00177-9
Children With Short Stature Display Reduced ACE2 Expression in Peripheral Blood Mononuclear Cells (2022) Frontiers in Endocrinology. 10.3389/fendo.2022.912064
Schisandrin B alleviates angiotensin II-induced cardiac inflammatory remodeling by inhibiting the recruitment of MyD88 to TLRs in mouse cardiomyocytes (2024) INTERNATIONAL IMMUNOPHARMACOLOGY. 10.1016/j.intimp.2024.112660
The protective role of Agrin and CAF22 in hypertensive nephropathy (2025) INTERNATIONAL IMMUNOPHARMACOLOGY. 10.1016/j.intimp.2025.115107
Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells (2022) NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. 10.1016/j.numecd.2022.01.029
Sex Differences in Proatherogenic Cytokine Levels (2020) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 10.3390/ijms21113861
Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II-Induced Cardiac Hypertrophy (2025) JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 10.1111/jcmm.70733
A longitudinal study on the effect of obesity upon circulating renin angiotensin system in normal pregnancy (2023) NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. 10.1016/j.numecd.2023.10.030
Oleanolic acid protects against pathogenesis of atherosclerosis, possibly via FXR-mediated angiotensin (Ang)-(1–7) upregulation (2017) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2017.11.151
